Clinical pharmacokinetics of suramin in patients with onchocerciasis

European Journal of Clinical Pharmacology

Volumn 54, Issue 3, 1998, Pages 249-251

  Chijioke, C P ^b,c   Umeh, R E ^b,c   Mbah, A U ^b,c   Nwonu, P ^b,c   Fleckenstein, L L ^a   Okonkwo, P O ^b,c  

^a UNIVERSITY OF IOWA   (United States)

^b Dept of Pharmacol and Therapeutics ^*  (United States)

^c UNIVERSITY OF NIGERIA   (Nigeria)

Author keywords

Onchocerciasis; Suramin

Indexed keywords

SURAMIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; HUMAN; MALE; ONCHOCERCIASIS; PRIORITY JOURNAL;

ADULT; ANIMALS; ANTINEMATODAL AGENTS; EXANTHEMA; FOOT; HUMANS; HYPOPIGMENTATION; MALE; METABOLIC CLEARANCE RATE; MICROFILARIA; MIDDLE AGED; ONCHOCERCA; ONCHOCERCIASIS; PARESTHESIA; PRURITUS; SKIN; SURAMIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031807496     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050454     Document Type: Article

References (12)

1. Awadzi K, Hero M, Opoku NO, Addy ET, Buttner DW, Ginger CD (1995) The chemotherapy of onchocerciasis XVIII. Aspects of treatment with suramin. Trop Med Parasitol 46: 19-26
2. Collins JM, Klecker RW, Yarchoan R, et al (1986) Clinical pharmacokinetics of suramin in patients with HTLV III-LAV Infection. J Clin Pharmacol 26: 22-26
3. Edwards G, Rodick CL, Ward SA, et al (1986) Disposition of suramin in patients with onchocerciasis. Acta Pharmacol Toxicol 59 [Suppl V]: 222
4. Jodrell DI, Reyno LM, Sridhara R, Eisenberger MA, Tkaczuk KH, Zuhowski EG, Sinibaldi VJ, Novak MJ, Egorin MJ (1994) Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. J Clin Oncol 12: 166-175
5. Kobayashi K, Vokes EE, Vogelzang NJ, Janisch L, Soliven B, Ratain MJ (1995) Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 13: 2196-2207
6. La Rocca RV, Meer J, Gilliatt RW, Stein CA, Cassidy J, Myers CE, Dalakas MC (1990) Suramin-induced polyneuropathy. Neurology 40: 954-960
7. Müller WE, Wollert U. Spectroscopic studies on the complex formation of suramin with bovine and human serum albumin (1976) Biochim Biophys Acta 427: 465-480
8. Reyno LM, Egorin MJ, Eisenberger MA, et al (1995) Development and validation of a pharmacokinetically-based fixed dosing scheme for suramin. J Clin Oncol 13: 2187-2195
9. Scher HI, Jodrell DI, Iversen JM, et al (1992) Use of adaptive control with feedback to individualize suramin dosing. Cancer Res 52: 64-70
10. Stein CA, Larocca RV, Thomas R, McAtee N, Myers CE (1989) Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 7: 499-505
11. Tong WP, Scher HI, Petrylak DP, et al (1990) A rapid assay of suramin in plasma. J Liq Chrom 13: 2269-2284
12. Wagner JG (1975) Fundamentals of clinical pharmacokinetics. Drug Intelligence Publications, Inc., Hamilton, Illinois